| Nancy Chiyeko Yoshiyama, PHARMD | |
|
4042 Rousseau Ln, Palos Verdes Peninsula, CA 90274-3948 | |
| (310) 265-8149 | |
| Not Available |
| Full Name | Nancy Chiyeko Yoshiyama |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 4042 Rousseau Ln, Palos Verdes Peninsula, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902486202 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 43844 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Nancy Chiyeko Yoshiyama, PHARMD 4042 Rousseau Ln, Palos Verdes Peninsula, CA 90274-3948 Ph: (310) 265-8149 | Nancy Chiyeko Yoshiyama, PHARMD 4042 Rousseau Ln, Palos Verdes Peninsula, CA 90274-3948 Ph: (310) 265-8149 |
News Archive
Scientists are reporting development and successful laboratory testing of an electrochemical sensor device that has the potential to measure blood sugar levels from tears instead of blood - an advance that could save the world's 350 million diabetes patients the discomfort of pricking their fingers for droplets of blood used in traditional blood sugar tests.
MedeAnalytics, a leading provider of healthcare performance management solutions, announced that Blue Shield of California (BSC) has extended its agreement for MedeAnalytics' Claims Transparency solution, which powers BSC's successful Partnership in Operational Excellence and Transparency (POET) program. BSC has partnered with nearly 100 California hospitals to improve claims performance metrics, streamline business processes and accelerate revenue cycles. The POET program has resulted in a significant decrease in the number of claims denials and appeals.
Allos Therapeutics, Inc. today reported results from a retrospective analysis of data from the Company's pivotal PROPEL trial which suggested that treatment with single-agent FOLOTYN may result in increased response rates and progression-free survival relative to the immediate prior line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
Patients with Wolff-Parkinson-White syndrome who receive catheter ablation to cure their abnormal heart rhythms are just as likely as non-ablated patients to develop atrial fibrillation no matter what age they receive ablation, according to a new study.
Results of two major clinical studies presented at ACC.11 - the 60th Annual Scientific Session & Expo of the American College of Cardiology - demonstrate that the Resolute drug-eluting stent from Medtronic, Inc., provides a positive and persistent treatment effect for a wide variety of patients with coronary artery disease.
› Verified 8 days ago